Latest News

Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer

STRASBOURG, France–(BUSINESS WIRE)–<a href="" target="_blank">#Transgene</a>–Regulatory News: Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, provides an update on the interim futility analysis of the PHOCUS study of Pexa-Vec in liver cancer. The independent Data Monitoring Committee (IDMC) of the PHOCUS trial has recommended to stop the study (see press release distributed on August 2, 2019). Transgene is currently analyzing the data of the trial it rec

Source link

Related posts

Tougher Rules on Opioids After Surgery Doesn't Mean More Pain for Patients


Coronavirus taking an economic toll on China


Medical News Today: Common pain relievers may worsen C. difficile infection


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy